Myriad to buy Javelin for $96 million
This article was originally published in Scrip
Executive Summary
Myriad Pharmaceuticals is to acquire Javelin Pharmaceuticals under an all-share merger agreement that values Javelin at $96 million based on Myriad's share price immediately preceding the announcement. The deal value could rise to nearly $113 million if Javelin's lead product, Dyloject (diclofenac sodium for injection), receives US FDA approval before the end of June 2010.